The Serum Institute of India said it will apply for a licence to start clinical trials of the coronavirus vaccine developed at Oxford University.
The Pune firm is the world’s largest vaccine maker in terms of the number of doses produced and sold globally. It has partnered with biopharmaceutical company AstraZeneca to mass produce the Oxford vaccine.
India is among the largest manufacturer of generic drugs and vaccines in the world.
The vaccine, called AZD1222, produced an immune response and was safe in early-stage clinical trials, according to trial results published in 'The Lancet' medical journal. The Oxford vaccine prompted an antibody response within 28 days and a T-cell response within 14 days.
Neutralising antibodies, which can disable the virus, were detected in most participants after one shot, and in all of them after two.
“The trials have shown promising results and we are extremely happy about it,” said Adar Poonawalla, chief executive officer of Serum Institute of India.
“We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine in large volumes.”
Asianet.in/News Desk: Asianet Online